jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Oct. 12, 2023

Aug. 20, 2024

jRCT2071230061

A Mass Balance Study of [14C] TAS5315 in Healthy Adult Subjects

A Mass Balance Study of [14C] TAS5315 in Healthy Adult Subjects

Ali Nasermoaddeli

Taiho Pharmaceutical Co., Ltd.

1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo

+81-3-3293-2455

th-tas5315_clinical@taiho.co.jp

Suto Kotaro

Taiho Pharmaceutical Co., Ltd.

1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo

+81-3-3293-2455

th-tas5315_clinical@taiho.co.jp

Complete

Oct. 30, 2023

6

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

1) Aged 18 or older and younger than 40 years at the time of consent
2) Weigh at least 45.0 kg at the time of screening tests with a body mass index (BMI, weight [kg]/[height {m}]2) ranging from 18.0 to < 25.0 kg/m2
3) Blood pressure and body temperature obtained in screening tests within the following ranges
a Systolic blood pressure (in supine position), 90 to 139 mmHg
b Diastolic blood pressure (in supine position), 40 to 89 mmHg
c Body temperature ranging from 35.0 to 37.4
4) Judged to be healthy by the investigator based on the examination findings (subjective symptoms and objective findings), blood pressure, pulse rate, body temperature, 12-lead ECG, and laboratory tests (hematology test, biochemistry test, and urinalysis) at the time of screening tests

1) Had any concurrent disease (including symptoms and signs; however, diseases that do not affect evaluations in the study such as asymptomatic pollinosis and wart are excluded)
2) Had any severe disease history that may recur during the study period.

18age old over
40age old not

Male

healthy adult males

Orally administration of 8 mL (containing 4 mg of TAS5315 and about 1 MBq of administered radioactivity) of the prepared solution

-Plasma and blood radioactivity concentrations, plasma TAS5315 concentrations and their pharmacokinetic parameters, and blood/plasma radioactivity concentration ratio
-Excretion and rate of radioactivity in urine and feces, cumulative excretion and cumulative excretion rate
-Total amount and rate of excretion of radioactivity in urine and feces, total amount and rate of cumulative excretion
-Metabolite profile and structural estimation of TAS5315 in plasma, urine and feces

Taiho Pharmaceutical Co., Ltd.
Hakata Clinic Institutional Review Board
6-18, Tenyamachi, Hakata-ku, Fukuoka City, Fukuoka

+81-92-283-7701

Approval

Oct. 13, 2023

No

なし

none

History of Changes

No Publication date
3 Aug. 20, 2024 (this page) Changes
2 Oct. 17, 2023 Detail Changes
1 Oct. 12, 2023 Detail